This medicine is now known as dilanubicel.
On 17 January 2018, orphan designation (EU/3/17/1958) was granted by the European Commission to Voisin Consulting S.A.R.L, France, for allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (also known as NLA101) for treatment in haematopoietic stem cell transplantation.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2021 on request of the Sponsor.
EU/3/17/1958: Public summary of opinion on orphan designation: Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 for treatment in haematopoietic stem cell transplantation (PDF/211.17 KB)
First published: 14/03/2018
Last updated: 22/03/2021
Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (dilanubicel)
Treatment in haematopoietic stem cell transplantation
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.